Feed aggregator

If you are a close contact of someone with COVID-19 or you are a resident in a community where there is ongoing spread of COVID-19 and develop symptoms of COVID-19, call your healthcare provider and tell them about your symptoms and your exposure.

Overview of Testing for SARS-CoV-2

Forecasts show national and state level cumulative reported and predicted deaths since the beginning of the pandemic. CDC is working with partners to bring together weekly COVID-19 forecasts in one place.

CDC COVID Data Tracker - Cases and Deaths by State

Systemic health and social inequities have put people from racial and ethnic minority groups at increased risk from COVID-19. Take steps to reduce health disparities.

COVID-19 vaccines are safe and effective. Millions of people in the United States have received COVID-19 vaccines, and these vaccines will undergo the most intensive safety monitoring in U.S. history. CDC recommends you get a COVID-19 vaccine as soon as you are eligible. Adverse events described on this page have been reported to the Vaccine Adverse Event Reporting System (VAERS).

CDC and its partners are monitoring reports of myocarditis and pericarditis. CDC continues to recommend COVID-19 vaccination for everyone 12 years of age and older.

FAQ for Healthcare Professionals

Answers to commonly asked questions about COVID-19 vaccines, including vaccine cost, availability, and types.

The World Health Organization has announced the recommended viral composition of influenza vaccines for the 2023 southern hemisphere influenza season.  

The recommendations issued today will be used by national vaccine regulatory agencies and pharmaceutical companies to develop, produce, and license influenza vaccines for the following influenza season. The periodic update of viruses contained in influenza vaccines is necessary for the vaccines to be effective due to the constantly evolving nature of influenza viruses. 

The recommendation is based on the advice of a group of experts from WHO Collaborating Centres and WHO Essential Regulatory Laboratories that analyze virus surveillance data generated by the WHO Global Influenza Surveillance and Response System (or GISRS).

Around a billion people get seasonal influenza every year and the threat of an influenza pandemic is ever-present. For this reason, the need to monitor circulating respiratory viruses, including influenza, continues to be critical. This monitoring informs the  vaccine composition recommendations that WHO issues twice a year.

The year-round surveillance is conducted by GISRS, a global network of over 150 laboratories in 127 countries, areas or territories set up in 1952.  This year we celebrate its 70th anniversary.

Going forward, GISRS will continue to use its unique position as a global respiratory surveillance network to add value to other respiratory virus threats, including COVID-19, where it has already played a significant role. It will also make use of emerging technologies, for example by expanding genomic surveillance, to continue to protect people from the threat of influenza.

Recommendations

WHO recommends that quadrivalent vaccines for use in the 2023 southern hemisphere influenza season contain the following: 

Egg-based vaccines

• an A/Sydney/5/2021 (H1N1)pdm09-like virus;
• an A/Darwin/9/2021 (H3N2)-like virus;
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

Cell culture- or recombinant-based vaccines

• an A/Sydney/5/2021 (H1N1)pdm09-like virus;
• an A/Darwin/6/2021 (H3N2)-like virus;
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

WHO recommends that trivalent vaccines for use in the 2023 southern hemisphere influenza season contain the following:  

Egg-based vaccines

• an A/Sydney/5/2021 (H1N1)pdm09-like virus;
• an A/Darwin/9/2021 (H3N2)-like virus; and
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell culture- or recombinant-based vaccines

• an A/Sydney/5/2021 (H1N1)pdm09-like virus;
• an A/Darwin/6/2021 (H3N2)-like virus; and
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus

 

Find links to resources for clinicians caring for patients with a suspected or confirmed infection caused by coronavirus disease 2019 (COVID-19).

Guidance to assist with assessment of risk, monitoring, and work restriction decisions for Healthcare Providers with potential exposure to COVID-19.

Guidance for healthcare professionals who have the potential for direct or indirect exposure to patients or infectious materials.

This guidance is to assist healthcare facilities in mitigating healthcare personnel staffing shortages that might occur because of COVID-19.

The Myocarditis Outcomes after mRNA COVID-19 Vaccination Investigation is a project to follow up on VAERS reports of myocarditis.

A review of the week's key data from CDC's COVID Data Tracker, narrative interpretations, and visualizations.

Strategy defines CDC program priorities & guides development of criteria for monitoring & evaluating impact for CDC's global response to the COVID-19 pandemic.

Because COVID-19 is a new disease with new vaccines, you may have questions about what happens before, during, and after your appointment to get vaccinated. These tips will help you know what to expect when you get vaccinated, what information your provider will give you, and resources you can use to monitor your health after you are vaccinated.